We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Eli Lilly’s Lebrikizumab Shows Positive Phase 3 Results for Atopic Dermatitis
Eli Lilly’s Lebrikizumab Shows Positive Phase 3 Results for Atopic Dermatitis
Eli Lilly’s IL-13 inhibitor lebrikizumab significantly improved disease severity when combined with topical corticosteroids in people with moderate-to-severe atopic dermatitis (AD) in the drug’s third pivotal phase 3 trial, the company said.